Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
An update from Lipocine ( (LPCN) ) is now available.
Lipocine presented posters for LPCN 2101 at the American Epilepsy Society Annual Meeting held from December 5th to 9th, 2025, in Atlanta, GA. This presentation could potentially enhance Lipocine’s visibility and influence within the epilepsy treatment sector, impacting its market positioning and stakeholder engagement.
The most recent analyst rating on (LPCN) stock is a Buy with a $7.00 price target. To see the full list of analyst forecasts on Lipocine stock, see the LPCN Stock Forecast page.
Spark’s Take on LPCN Stock
According to Spark, TipRanks’ AI Analyst, LPCN is a Neutral.
Lipocine’s overall stock score is primarily impacted by its financial performance and valuation. While the company shows signs of financial recovery with a strong balance sheet, ongoing profitability challenges and negative cash flow generation weigh heavily on the score. The technical analysis indicates a bearish trend, further contributing to the lower score. The lack of earnings call data and corporate events means these factors do not influence the score.
To see Spark’s full report on LPCN stock, click here.
More about Lipocine
Average Trading Volume: 43,091
Technical Sentiment Signal: Sell
Current Market Cap: $18.15M
For a thorough assessment of LPCN stock, go to TipRanks’ Stock Analysis page.